The emergence of drug-resistant viral infections poses a significant challenge to global public health. Traditional antiviral therapies have shown limited efficacy against rapidly mutating viral strains, necessitating the development of novel therapeutic strategies. This study aims to evaluate the efficacy and safety of new antiviral compounds designed to target resistant viral infections. A multi-center, double-blind, placebo-controlled clinical trial was conducted over 12 months, involving 1,200 participants across three continents. Participants were randomly assigned to receive either the experimental antiviral therapy or a placebo. Outcomes were measured in terms of viral load reduction, symptom alleviation, and adverse effects. The study found that the novel antiviral therapy significantly reduced viral load within two weeks of administration compared to the placebo group. Additionally, patients reported improved symptoms without serious adverse effects, suggesting a favorable safety profile. These findings indicate that the new antiviral compounds offer a promising alternative to existing treatments, particularly for patients with resistant viral infections. Further research is recommended to explore long-term efficacy and potential resistance development. The study concludes that innovative antiviral therapies can fill critical gaps in current treatment options, potentially transforming resistance management.